US FDA refuses to approve first MDMA-based treatment for PTSD
The U.S. FDA has refused to approve a mind-altering MDMA-based therapy for patients with post-traumatic stress disorder, saying it cannot be approved based on the data submitted, developer Lykos Therapeutics said.
BELIEBTE BEITRÄGE
UK sets new climate target for 2035
November 13, 2024
Children go back to school after Valencia floods
November 13, 2024
Researchers document huge decline in African elephants
November 13, 2024
Mission: Impossible 8 title revealed
November 13, 2024
LIVEÜBERTRAGUNG